论文部分内容阅读
本文旨在识别与慢性粒细胞白血病(CGL)长期生存有关的最初临床血液学指标,并分析长期生存者预后模型的精确性。 选择了813例Ph~- CGL慢性期患者,男性464例,女性349例,中位年龄43(5～84)岁,随诊至少10年。多数患者接受单一药物化疗(多为马利兰),少数患者还行脾切除或大剂量联合化疗,10%的患者尚辅以免疫治疗。以Sokal指数及派生的新预后指数识别长期生存者。用这些指数以计算其正性及负性预后准确性、敏感性及特异性,预后准确性呈正性是指初诊时预测为“预后良好组”中最终成为长期
This article aims to identify the initial clinical hematology indicators associated with the long-term survival of chronic myeloid leukemia (CGL) and analyze the accuracy of the long-term prognostic model. A total of 813 Ph ~ - CGL patients were selected, 464 males and 349 females, with a median age of 43 (range, 5-84) years and at least 10 years of follow-up. Most patients receive single-agent chemotherapy (mostly Maryland), and a small number of patients underwent splenectomy or high-dose chemotherapy in combination with 10% of patients receiving adjuvant immunotherapy. Long-term survivors were identified using the Sokal index and the new prognostic index. These indices are used to calculate the positive and negative prognostic accuracy, sensitivity and specificity, and the positive prognostic accuracy means that the prognosis is “long-term prognosis” at the first diagnosis